Therefore, the development of novel approaches for the detection of early lung cancer-specific markers for personalized treatment is urgently needed to increase patient survival in lung cancer treatment.
Such model diseases might be used to develop and apply the methods required to find markers for personalized medicine.
This high frequency of mutation and the high copy number of mitochondria per cell suggest that mtDNA mutations may be useful markers for personalized assessment of cancer.
The main problems involved in finding markers for personalized dosage are that each complex disease may involve altered interactions between hundreds or thousands of genes that can differ among patients.
Now, the large-scale analysis of proteins (proteomics) is a mainstay of biological research and clinical translation, with researchers seeking molecular diagnostics, as well as protein-based markers for personalized medicine.
Ideally, a study aiming to find markers for personalized medication would involve a known external cause, a key cell type, and a read-out, all of which can be studied experimentally in patient samples.
